Liposomes and nanotechnology in drug development: focus on ocular targets.
Liposomes and nanotechnology in drug development: focus on ocular targets.
复制标题
DOI：
10.2147/ijn.s30725
复制
发表时间：
2013
影响因子：
8
通讯作者：
Ebihara N
中科院分区：
文献类型：
--
作者：
Honda M;Asai T;Oku N;Araki Y;Tanaka M;Ebihara N
患者眼部病变的药物递送不良是眼部疾病治疗的主要障碍。这些区域药物的可及性受到屏障存在的高度限制，包括角膜屏障、水屏障和内外血视网膜屏障。特别是，由于其结构的特殊性，后段很难达到药物。本文讨论了药物传递的各种障碍，并为设计用于治疗眼部疾病的纳米颗粒介导的药物传递系统提供了全面的信息。纳米颗粒可以被设计成改善渗透、控制释放和药物靶向。正如这篇综述所强调的，眼部疾病的药物治疗效果已经被报道通过使用纳米颗粒如脂质体、微/纳米球、微乳液和树状大分子来提高。我们最近的数据表明，玻璃体内注射包裹血管生成抑制剂的靶向脂质体对脉络膜新生血管的抑制作用明显大于注射游离药物。眼部药物传递系统研究的最新进展为药物开发提供了新的见解，因此使用纳米颗粒进行药物传递是一种有希望的眼部疾病高级治疗方法。
Poor drug delivery to lesions in patients’ eyes is a major obstacle to the treatment of ocular diseases. The accessibility of these areas to drugs is highly restricted by the presence of barriers, including the corneal barrier, aqueous barrier, and the inner and outer blood–retinal barriers. In particular, the posterior segment is difficult to reach for drugs because of its structural peculiarities. This review discusses various barriers to drug delivery and provides comprehensive information for designing nanoparticle-mediated drug delivery systems for the treatment of ocular diseases. Nanoparticles can be designed to improve penetration, controlled release, and drug targeting. As highlighted in this review, the therapeutic efficacy of drugs in ocular diseases has been reported to be enhanced by the use of nanoparticles such as liposomes, micro/nanospheres, microemulsions, and dendrimers. Our recent data show that intravitreal injection of targeted liposomes encapsulating an angiogenesis inhibitor caused significantly greater suppression of choroidal neovascularization than did the injection of free drug. Recent progress in ocular drug delivery systems research has provided new insights into drug development, and the use of nanoparticles for drug delivery is thus a promising approach for advanced therapy of ocular diseases.